JOHNNY MADSEN
CHIEF INVESTMENT OFFICER
FORMUE- & INVESTERINGSPLEJE
Score prediction: DENMARK 0 – BELGIUM 2
INVESTMENT INSIGHT:
Novo Nordisk is a leading global company in diabetes. The company has a strong product portfolio, and a strong R&D pipeline. The company has a market share of 29.3% in Q1 2021 and the ambitions is to have a market share of more than 33% in diabetes in 2025.
Over all the diabetes market is expecting to grow with 4% p.a. in the coming years, and Novo Nordisk expect to grow more.
Novo Nordisk has become a global leader in the medical treatment against obesity and a newly launched product – Saxenda – has shown a documented weight loss of 5-10% over time.
Additionally, Novo Nordisk has several promising new products in the pipeline, where the ambition is a weight loss of 15-30%.
We believe Novo Nordisk can achieve this, and obesity then can become an important growth driver for the company in many years ahead.
STEFAAN CASTELEYN
PARTNER
1VERMOGENSBEHEER
Score prediction: DENMARK 1 – BELGIUM 2
INVESTMENT INSIGHT:
Will the BEL20-index reach an all time high this year ?
The Belgian major stock index, BEL20, was created in 1990. The index is a price index and started at 1,000 points on 1/1/1990. Today we are at 4,100 points, so the index quadruppled in a little more than 30 years.
This looks quite good but the index reached it’s ‘all time high’ of 4,690 points on 17 May 2007 – so more than 14 years ago.
The BEL20 needs to rise by a little more than 14% to reach it’s highest point ever. Could this point be reached this year?
Although this is still a way to go, this indeed is possible. Belgians have more than €300bn stashed away in savings accounts that yield no intrest. On top of that, it is estimated that at least a similar amount is placed in other non-yielding investments.
If only a limited part of all this cash (thanks to optimism after winning the European Championships?) is invested in local stocks, the BEL20 could finally pass the 14-year old all time high.
